Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions: Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention, Usual Care; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV Infections
Interventions: Optimized Background Therapy (OBT), maraviroc (UK-427,857); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more

Conditions: Pediatric Disorder
Interventions: Acetaminophen, Ibuprofen; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 3 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Tobacco Use Disorder, Substance Use Disorder
Interventions: Focus Group, Contingency Management (CM), TUD Treatment as Usual (TAU); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions: Quetiapine; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 4
States / cities: Augusta, Georgia • Lebanon, New Hampshire • Manchester, New Hampshire

Conditions: Pancreatic Fistula
Interventions: Piperacillin/Tazobactam, Amoxicillin/ Clavulanic acid; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 90 Years
Enrollment: 587 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 47 more

Conditions: Gastrointestinal Disease, Colorectal Cancer
Interventions: Pure-Vu System; Device
Lead sponsor: Motus GI Medical Technologies Ltd; Industry
Eligibility: 22 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mantle Cell Lymphoma, B Cell Lymphoma, Multiple Myeloma
Interventions: Canfosfamide HCl for injection; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: HIV Infection
Interventions: All licensed antiretroviral medications; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 4,688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 55
States / cities: Alhambra, California • Los Angeles, California • San Diego, California + 37 more

Conditions: Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Spondylolisthesis, Lumbar Spondylosis, Lumbar Radiculopathy, Lumbar Spine Instability, Synovial Cyst, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Intervertebral Discs
Interventions: Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine, normal saline; Drug
Lead sponsor: John O'Toole; Other
Eligibility: 18 Years to 80 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Vascular Reactivity, Serum Biomarkers
Interventions: Standardized Electronic Research Cigarette, Nicotine Research Cigarette; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hemorrhage, Healthy
Interventions: Ketamine Hydrochloride, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Osteoporosis
Interventions: alendronate with cholecalciferol, calcium carbonate with cholecalciferol, Falls prevention measures; Drug · Behavioral
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 65 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Physical Activity
Interventions: Additional Muscle Biopsy Collection; Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Chronic Daily Headache
Interventions: Diet A, Diet B; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Rectal Cancer
Interventions: Epacadostat, Short-course radiation therapy, CAPOX chemotherapy, FOLFOX chemotherapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 4
States / cities: Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more

Conditions: Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 5 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cancer, Chemotherapy Effect
Interventions: Onco4D Biodynamic Chemotherapy Selection Assay; Diagnostic Test
Lead sponsor: Animated Dynamics, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Asthma
Interventions: FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 38
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more

Conditions: Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Interventions: FARAPOINT Pulsed Field Ablation System, OptiMap System (non-ablative), FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Jonesboro, Arkansas • Santa Monica, California • Athens, Georgia + 8 more

Conditions: Staphylococcus Aureus
Interventions: Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo; Biological
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • Portsmouth, Virginia

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 25
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more

Conditions: Healthy
Interventions: Lofexidine + Naltrexone; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

Comparing the Difference in Pain Control in the Pediatric General Surgery Population: to Alternate or Combine Acetaminophen and Ibuprofen?

Smoking Cessation CM for Veterans With or at Risk for Cancer

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Strategic Timing of Antiretroviral Treatment

Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery

MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine

Secondary Prevention of Osteoporosis

Investigating the Effects of Aerobic and Resistance Training in Vivo on Skeletal Muscle Metabolism in Vitro in Primary Human Muscle Cells (MoTrMyo)

Nutrition for Chronic Daily Headache

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

Measuring the Impact of Onco4D® Guidance on Chemotherapy Selection and Outcomes

Fall Epidemic Viral Pediatric Study

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects